Home › Kanser sa Pancreas › North Carolina › Durham
Pag-aaral pangklinika para sa Kanser sa Pancreas sa Durham, NC
24 pag-aaral para sa Kanser sa Pancreas ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Durham (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
A Study of PHN-012 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1
- PHN-012-001 Site, Durham
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Nagre-recruitPhase 3
- Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
- Research Site, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Nagre-recruitPhase 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi ang layo
- University of North Carolina Hospitals at Hillsborough, Hillsborough · 13 mi ang layo
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Nagre-recruitPhase 3
- Duke Cancer Center, Durham
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Nagre-recruitPhase 3
- Investigative Site US035, Chapel Hill · 10 mi ang layo
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Nagre-recruitPhase 1/2
- Duke University Medical Center, Durham
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Nagre-recruitPhase 2
- Local Institution - 0100, Durham
Promoting CT Engagement for Pancreatic Cancer With App
Nagre-recruit
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Nagre-recruitObservasyonal na pag-aaral
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi ang layo
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Nagre-recruitPhase 2
- University of North Carolina, Chapel Hill · 10 mi ang layo
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Nagre-recruitPhase 1
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 10 mi ang layo
- University of North Carolina, Chapel Hill · 10 mi ang layo
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Nagre-recruitPhase 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Nagre-recruitPhase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Nagre-recruitPhase 2
- Duke University Medical Center, Durham
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Nagre-recruitPhase 1
- Duke Cancer Institute /ID# 276267, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Nagre-recruitPhase 1
- Research Site, Durham
Autologous CAR-T Cells Targeting B7-H3 in PDAC
Nagre-recruitPhase 1
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Nagre-recruitPhase 1
- Duke Cancer Center, Durham
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Nagre-recruitPhase 1/2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Nagre-recruitPhase 2
- University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi ang layo
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Nagre-recruitPhase 2
- University of North Carolina, Chapel Hill · 10 mi ang layo
Pag-aaral para sa Kanser sa Pancreas sa ibang lungsod
- Houston, TX61 pag-aaral
- New York City, NY60 pag-aaral
- Boston, MA43 pag-aaral
- Nashville, TN39 pag-aaral
- Los Angeles, CA35 pag-aaral
- St. Louis, MO33 pag-aaral
- Arlington, VA33 pag-aaral
- Baltimore, MD31 pag-aaral
- San Antonio, TX31 pag-aaral
- Philadelphia, PA26 pag-aaral
- Tampa, FL26 pag-aaral
- San Diego, CA24 pag-aaral
Iba pang pag-aaral sa Durham
- Kanser sa Suso64 pag-aaral
- Kanser (lahat ng uri)58 pag-aaral
- Non-Small Cell Lung Cancer39 pag-aaral
- Multiple Myeloma37 pag-aaral
- Acute Myeloid Leukemia33 pag-aaral
- Metastatic Cancer33 pag-aaral
- Kanser sa Prostate32 pag-aaral
- Kanser sa Baga32 pag-aaral
- Colorectal Cancer28 pag-aaral
- Kanser sa Ovary27 pag-aaral
- Chronic Lymphocytic Leukemia27 pag-aaral
- Pagkabigo ng Puso26 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.